NCIt definition : A monoclonal antibody directed against a specific epitope of the insulin-like growth
factor-binding protein 7 (IGFBP7) receptor complement component C1q receptor (C1QR1;
CD93), with potential antineoplastic activity. Upon administration, anti-CD93 monoclonal
antibody DCSZ11 targets and binds to CD93 expressed on tumor-associated endothelial
cells. This prevents the interaction of CD93 with its ligand IGFBP7, which improves
tumor vascular function, reduces tumor hypoxia and increases tumor perfusion. This
enhances immune cell infiltration into the tumor microenvironment (TME) and inhibits
tumor cell proliferation. CD93 blockade and the normalization of tumor vasculature
may also improve the delivery of other antineoplastic agents, thereby enhancing their
antitumor effect. In addition, by increasing intratumoral effector T-cells in the
TME, DCSZ11 may enhance the efficacy of certain immunotherapeutic agents. CD93, a
C-type lectin transmembrane protein, is upregulated in tumor-associated endothelial
cells. Its expression is correlated with tumor vascular dysfunction and decreased
immune cell infiltration.;
Semantic type(s)